Roche has received emergency clearance from the U.S. FDA for its innovative four-in-one molecular test that detects SARS-CoV-2, influenza A/B viruses, and RSV. This test utilizes highly sensitive PCR technology and requires only a single nasal swab sample to provide qualitative detection and rapid, accurate differentiation among these prevalent respiratory viruses.
With results available in just 20 minutes, healthcare professionals can confidently make clinical decisions and quickly determine appropriate treatments. This rapid turnaround time is crucial in managing and controlling the spread of these respiratory infections, ensuring patients receive the most suitable care promptly.
"Diagnostics play a vital role in the fight against respiratory diseases," said Matt Sause, CEO of Roche Diagnostics. "We are proud to offer this groundbreaking test to alleviate the significant burden on healthcare systems. It allows healthcare professionals to detect and differentiate these respiratory viruses in a single patient visit, ultimately improving public health outcomes."
Click here to read the original news story.